Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel

Clinical Cancer Research

Volumn 6, Issue 7, 2000, Pages 2635-2643

  Inoue, Keiji ^a   Slaton, Joel W ^a   Davis, Darren W ^a   Hicklin, Daniel J ^b   McConkey, David J ^a   Karashima, Takashi ^a   Radinsky, Robert ^a   Dinney, Colin P N ^a,c  

^a UNIVERSITY OF TEXAS   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; GELATINASE B; INTERLEUKIN 8; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY DC101; PACLITAXEL; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLADDER CARCINOMA; CANCER GROWTH; CANCER INHIBITION; CANCER REGRESSION; CARCINOGENESIS; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HUMAN CELL; LYMPH NODE METASTASIS; MOUSE; NONHUMAN; ORGAN WEIGHT; PRIORITY JOURNAL; TRANSITIONAL CELL CARCINOMA;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; APOPTOSIS; CARCINOMA, TRANSITIONAL CELL; CELL DIVISION; ENDOTHELIAL GROWTH FACTORS; FIBROBLAST GROWTH FACTOR 2; HUMANS; INTERLEUKIN-8; LYMPHOKINES; MALE; MATRIX METALLOPROTEINASE 9; MICE; MICE, NUDE; MICROCIRCULATION; NEOVASCULARIZATION, PATHOLOGIC; PACLITAXEL; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RNA, MESSENGER; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED; URINARY BLADDER NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0033927807     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (84)

1. Folkman, J. Angiogenesis: initiation and modulation. Symp. Fundam. Cancer Res., 36: 201-208, 1983.
2. Folkman, J. Tumor angiogenesis. Adv. Cancer Res., 43: 175-203, 1985.
3. Folkman, J. How is blood vessel growth regulated in normal and neoplastic tissue? G. H. A. Clowes Memorial Award Lecture. Cancer Res., 46: 467-473, 1986.
4. Folkman, J. What is the evidence that tumors are angiogenesis dependent? J. Natl. Cancer Inst., 82: 4-6, 1990.
5. Ravery, V., Jouanneau, J., Gil, D. S., Abbou, C. C., Caruelle, J. P., Barritault, D., and Chopin, D. K. Immunohistochemical detection of acidic fibroblast growth factor in bladder transitional cell carcinoma. Urol. Res., 20: 211-214, 1992.
6. Allen, L. E., and Maher, P. A. Expression of basic fibroblast growth factor and its receptor in an invasive bladder carcinoma cell line. J. Cell. Physiol., 155: 368-375, 1993.
7. Tachibana, M., Miyakawa, A., Nakashima, J., Murai, M., Nakamura, K., Kubo, A., and Hata, J. I. Constitutive production of multiple cytokines and a human chorionic gonadotrophin β-subunit by a human bladder cancer cell line (KU-19-19): possible demonstration of totipotential differentiation. Br. J. Cancer, 76: 163-174, 1997.
8. O'Brien, T., Cranston, D., Fuggle, S., Bicknell, R., and Harris, A. L. The angiogenic factor midkine is expressed in bladder cancer, and overexpression correlates with a poor outcome in patients with invasive cancers. Cancer Res., 56: 2515-2518, 1996.
9. Bellusci, S., Moens, G., Gaudino, G., Comoglio, P., Nakamura, T., Thiery, J. P., and Jouanneau, J. Creation of an hepatocyte growth factor/scatter factor autocrine loop in carcinoma cells induces invasive properties associated with increased tumorigenicity. Oncogene, 9: 1091-1099, 1994.
10. Li, B., Kanamaru, H., Noriki, S., Fukuda, M., and Okada, K. Differential expression of hepatocyte growth factor in papillary and nodular tumors of the bladder. Int. J. Urol., 5: 436-440, 1998.
11. O'Brien, T. S., Fox, S. B., Dickinson, A. J., Turley, H., Westwood, M., Moghaddam, A., Gatter, K. C., Bicknell, R., and Harris, A. L. Expression of the angiogenic factor thymidine phosphorylase/platelet-derived endothelial cell growth factor in primary bladder cancers. Cancer Res., 56: 4799-4804, 1996.
12. Kubota, Y., Miura, T., Moriyama, M., Noguchi, S., Matsuzaki, J., Takebayashi, S., and Hosaka, M. Thymidine phosphorylase activity in human bladder cancer: difference between superficial and invasive cancer. Clin. Cancer Res., 3: 973-976, 1997.
13. Coombs, L. M., Pigott, D. A., Eydmann, M. E., Proctor, A. J., and Knowles, M. A. Reduced expression of TGF β is associated with advanced disease in transitional cell carcinoma. Br. J. Cancer, 67: 578-584, 1993.
14. Eder, I. E., Stenzl, A., Hobisch, A., Cronauer, M. V., Bartsch, G., and Klocker, H. Expression of transforming growth factors β-1, β-2 and β-3 in human bladder carcinomas. Br. J. Cancer, 75: 1753-1760, 1997.
15. Crew, J. P., O'Brien, T., Bradburn, M., Fuggle, S., Bicknell, R., Cranston, D., and Harris, A. L. Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. Cancer Res., 57: 5281-5285, 1997.
16. Droller, M. J. Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. J. Urol., 160: 1932, 1998.
17. O'Brien, T., Cranston, D., Fuggle, S., Bicknell, R., and Harris, A. L. Different angiogenic pathways characterize superficial and invasive bladder cancer. Cancer Res., 55: 510-513, 1995.
18. Sato, K., Sasaki, R., Ogura, Y., Shimoda, N., Togashi, H., Terada, K., Sugiyama, T., Kakinuma, H., Ogawa, O., and Kato, T. Expression of vascular endothelial growth factor gene and its receptor (flt-1) gene in urinary bladder cancer. Tohoku J. Exp. Med., 185: 173-184, 1998.
19. de Vries, C., Escobedo, J. A., Ueno, H., Houck, K., Ferrara, N., and Williams, L. T. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science (Washington, DC), 255: 989-991, 1992.
20. Ferrara, N., Houck, K. A., Jakeman, L. B., Winer, J., and Leung, D. W. The vascular endothelial growth factor family of polypeptides. J. Cell. Biochem., 47: 211-218, 1991.
21. Leung, D. W., Cachianes, G., Kuang, W. J., Goeddel, D. V., and Ferrara, N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science (Washington, DC), 246: 1306-1309, 1989.
22. Asano, M., Yukita, A., Matsumoto, T., Matsuo, K., Kondo, S., and Suzuki, H. Isolation and characterization of neutralizing monoclonal antibodies to human vascular endothelial growth factor/vascular permeability factor121 (VEGF/VPF121). Hybridoma, 14: 475-480, 1995.
23. Samoto, K., Ikezaki, K., Ono, M., Shono, T., Kohno, K., Kuwano, M., and Fukui, M. Expression of vascular endothelial growth factor and its possible relation with neovascularization in human brain tumors. Cancer Res., 55: 1189-1193, 1995.
24. Claffey, K. P., Brown, L. F., del Aguila, L. F., Tognazzi, K., Yeo, K. T., Manseau, E. J., and Dvorak, H. F. Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis. Cancer Res., 56: 172-181, 1996.
25. Takahama, M., Tsutsumi, M., Tsujiuchi, T., Kido, A., Sakitani, H., Iki, K., Taniguchi, S., Kitamura, S., and Konishi, Y. Expression of vascular endothelial growth factor and its receptors during lung carcinogenesis by N-nitrosobis(2-hydroxypropyl)amine in rats. Mol. Carcinog., 24: 287-293, 1999.
26. Brown, L. F., Berse, B., Jackman, R. W., Tognazzi, K., Manseau, E. J., Senger, D. R., and Dvorak, H. F. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res., 53: 4727-4735, 1993.
27. Takahashi, Y., Cleary, K. R., Mai, M., Kitadai, Y., Bucana, C. D., and Ellis, L. M. Significance of vessel count and vascular endothelial growth factor and its receptor (KDR) in intestinal-type gastric cancer. Clin. Cancer Res., 2: 1679-1684, 1996.
28. Takahashi, Y., Kitadai, Y., Bucana, C. D., Cleary, K. R., and Ellis, L. M. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res., 55: 3964-3968, 1995.
29. Brown, L. F., Berse, B., Jackman, R. W., Tognazzi, K., Manseau, E. J., Dvorak, H. F., and Senger, D. R. Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am. J. Pathol., 143: 1255-1262, 1993.
30. Joukov, V., Pajusola, K., Kaipainen, A., Chilov, D., Lahtinen, I., Kukk, E., Saksela, O., Kalkkinen, N., and Alitalo, K. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. [published erratum in EMBO J., 15: 1751, 1996]. EMBO J., 15: 290-298, 1996.
31. Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., and Ferrara, N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature (Lond.), 362: 841-844, 1993.
32. Saleh, M., Stacker, S. A., and Wilks, A. F. Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence. Cancer Res., 56: 393-401, 1996.
33. Zhu, Z., Rockwell, P., Lu, D., Kotanides, H., Pytowski, B., Hicklin, D. J., Bohlen, P., and Witte, L. Inhibition of vascular endothelial growth factor-induced receptor activation with anti-kinase insert domain-containing receptor single-chain antibodies form a phase display library. Cancer Res., 58: 3209-3214, 1998.
34. Strawn, L. M., McMahon, G., App, H., Schreck, R., Kuchler, W. R., Lonhi, M. P., Hui, T. H., Tang, C., Levitzki, A., Gazit, A., Chen, I., Kerin, G., Orki, L., Risau, W., Flamme, I., Ullrich, A., Hirth, K. P., and Shawver, L. K. Flk-1 as a target for tumor growth inhibition. Cancer Res., 56: 3540-3545, 1996.
35. Fong, T. A., Shawver, L. K., Sun, L., Tang, C., App, H., Powell, T. J., Kim, Y. H., Schreck, R., Wang, X., Risau, W., Ullrich, A., Hirth, K. P., and McMahon, G. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res., 59: 99-106, 1999.
36. Arora, N., Masood, R., Zheng, T., Cai, J., Smithe, D. L., and Gill, P. S. Vascular endothelial growth factor chimeric toxin is highly active against endothelial cells. Cancer Res., 59: 183-188, 1999.
37. Ramakrishnan, S., Olson, T. A., Bautch, V. L., and Mohanraj, D. Vascular endothelial growth factor-toxin conjugate specifically inhibits KDR/flk-1-positive endothelial cell proliferation in vitro and angiogenesis in vivo. Cancer Res., 56: 1324-1330, 1996.
38. Witte, L., Hicklin, D. J., Zhu, Z., Pytowski, B., Kotanides, H., Rockwell, P., and Bohlen, P. Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy. Cancer Metastasis Rev., 17: 155-161, 1998.
39. Prewett, M., Huber, J., Li, Y., Santiago, A., O'Connor, W., King, K., Overholser, J., Hooper, A., Pytowski, B., Witte, L., Bohlen, P., and Hicklin, D. J. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res., 59: 5209-5218, 1999.
40. Dinney, C. P., Fishbeck, R., Singh, R. K., Eve, B., Pathak, S., Brown, N., Xie, B., Fan, D., Bucana, C. D., Fidler, I. J., and Killion, J. J. Isolation and characterization of metastatic variants from human transitional cell carcinoma passaged by orthotopic implantation in athymic nude mice. J. Urol., 154: 1532-1538, 1995.
41. Rogelj, S., Weinberg, R. A., Fanning, P., and Klagsbrun, M. Basic fibroblast growth factor fused to a signal peptide transforms cells. Nature (Lond.), 331: 173-175, 1988.
42. Berse, B., Brown, L. F., Van de Water, L., Dvorak, H. F., and Senger, D. R. Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. Mol. Biol. Cell., 3: 211-220, 1992.
43. Matsushima, K., Morishita, K., Yoshimura, T., Lavu, S., Kobayashi, Y., Lew, W., Appella, E., Kung, H. F., Leonard, E. J., and Oppenheim, J. J. Molecular cloning of a human monocyte-derived neutrophil chemotactic factor (MDNCF) and the induction of MDNCF mRNA by interleukin 1 and tumor necrosis factor. J. Exp. Med., 167: 1883-1893, 1988.
44. Greene, G. F., Kitadai, Y., Pettaway, C. A., von Eschenbach, A., Bucana, C. D., and Fidler, I. J. Correlation of metastasis-related gene expression with metastatic potential in human prostate carcinoma cells implanted in nude mice using an in situ messenger RNA hybridization technique. Am. J. Pathol., 150: 1571-1582, 1997.
45. Kitadai, Y., Bucana, C. D., Ellis, L. M., Anzai, H., Tahara, E., and Fidler, I. J. In situ mRNA hybridization technique for analysis of metastasis-related genes in human colon carcinoma cells. Am. J. Pathol., 147: 1238-1247, 1995.
46. Radinsky, R., Bucana, C. D., Ellis, L. M., Sanchez, R., Cleary, K. R., Brigati, D. J., and Fidler, I. J. A rapid colorimetric in situ messenger RNA hybridization technique for analysis of epidermal growth factor receptor in paraffin-embedded surgical specimens of human colon carcinomas. Cancer Res., 53: 937-943, 1993.
47. Bucana, C. D., Radinsky, R., Dong, Z., Sanchez, R., Brigati, D. J., and Fidler, I. J. A rapid colorimetric in situ mRNA hybridization technique using hyperbiotinylated oligonucleotide probes for analysis of mdr1 in mouse colon carcinoma cells. J. Histochem. Cytochem., 41: 499-506, 1993.
48. Reed, J. A., Manahan, L. J., Park, C. S., and Brigati, D. J. Complete one-hour immunocytochemistry based on capillary action. Biotechniques, 13: 434-443, 1992.
49. Perrotte, P., Matsumoto, T., Inoue, K., Kuniyasu, H., Eve, B. Y., Hicklin, D. J., Radinsky, R., and Dinney, C. P. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin. Cancer Res., 5: 257-265, 1999.
50. Vecchi, A., Garlanda, C., Lampugnani, M. G., Resnati, M., Matteucci, C., Stoppacciaro, A., Schnurch, H., Risau, W., Ruco, L., Mantovani, A., and Dejana, E. Monoclonal antibodies specific for endothelial cells of mouse blood vessels. Their application in the identification of adult and embryonic endothelium. Eur. J. Cell. Biol., 63: 247-254, 1994.
51. Weidner, N., Semple, J. P., Welch, W. R., and Folkman, J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N. Engl. J. Med., 324: 1-8, 1991.
52. Sternberg, C. N., Yagoda, A., Scher, H. I., Watson, R. C., Geller, N., Herr, H. W., Morse, M. J., Sogani, P. C., Vaughan, E. D., Bander, N., Weiselberg, L., Rosado, K., Smart, T., Lin, S-Y., Penenberg, D., Fair, W. R., and Whitmore, W. F., Jr. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer (Phila.), 64: 2448-2458, 1989.
53. Logothetis, C. J., Dexeus, F. H., Finn, L., Sella, A., Amato, R. J., Ayala, A. G., and Kilbourn, R. G. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J. Clin. Oncol., 8: 1050-1055, 1990.
54. Logothetis, C. J., Finn, L. D., Smith, T., Kilbourn, R. G., Ellerhorst, J. A., Zukiwski, A. A., Sella, A., Tu, S. M., and Amato, R. J. Escalated MVAC with or without recombinant human granulocyte-macrophage colony-stimulating factor for initial treatment of advanced malignant urothelial tumors: results of a randomized trial. J. Clin. Oncol., 13: 2272-2277, 1995.
55. Dinney, C. P., Bielenberg, D. R., Perrotte, P., Reich, R., Eve, B. Y., Bucana, C. D., and Fidler, I. J. Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-α administration. Cancer Res., 58: 808-814, 1998.
56. Slaton, J. W., Perrotte, P., Inoue, K., Dinney, C. P., and Fidler, I. J. Interferon-α-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin. Cancer Res., 5: 2726-2734, 1999.
57. Ye, D., Mendelsohn, J., and Fan, Z. Augmentation of a humanized anti-HER2 Mab 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor Mab C225. Oncogene, 18: 731-738, 1999.
58. Tortora, G., Caputo, R., Pomatico, G., Pepe, S., Bianco, A. R., Agrawal, S., Mendelsohn, J., and Ciardiello, F. Cooperative inhibitory effect of novel mixed backbone oligonucleotide targeting protein kinase A in combination with docetaxel and anti-epidermal growth factor-receptor antibody on human breast cancer cell growth. Clin. Cancer Res., 5: 875-881, 1999.
59. Ciardiello, F., Bianco, R., Damiano, V., De Lorenzo, S., Pepe, S., De Placido, S., Fan, Z., Mendelsohn, J., Bianco, A. R., and Tortora, G. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin. Cancer Res., 5: 909-916, 1999.
60. Baselga, J., Norton, L., Masui, H., Pandiella, A., Coplan, K., Miller, W. J., and Mendelsohn, J. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J. Natl. Cancer Inst., 85: 1327-1333, 1993.
61. Fan, Z., Baselga, J., Masui, H., and Mendelsohn, J. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res., 53: 4637-4642, 1993.
62. Roth, B. J., Dreicer, R., Einhorn, L. H., Neuberg, D., Johnson, D. H., Smith, J. L., Hudes, G. R., Schultz, S. M., and Loehrer, P. J. Significant activity of paclitaxel in advanced transitional cell carcinoma of the urothelium: a Phase II trial of the Eastern Cooperative Oncology Group. J. Clin. Oncol., 12: 2264-2270, 1994.
63. Vaughn, D. J., Malkowicz, S. B., Zoltick, B., Mick, R., Ramchandani, P., Holroyde, C., Armstead, B., Fox, K., and Wein, A. Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: an active and tolerable outpatient regimen. J. Clin. Oncol., 16: 255-260, 1998.
64. Redman, B. G., Smith, D. C., Flaherty, L., Du, W., and Hussain, M. Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma. J. Clin. Oncol., 16: 1844-1848, 1998.
65. Bajorin, D. F, McCafrey, J. A., Hilton, S., Mazumdar, M., Kelly, W. K., Scher, H. I., Spicer, J., Herr, H., and Higgins, G. Treatment of patients with transitional-cell carcinoma of the urothelial tract with ifosfamide, paclitaxel, and cisplatin: a Phase II trial. J. Clin. Oncol., 16: 2722-2727, 1998.
66. Horwitz, S. B. Mechanism of action of taxol. Trends Pharmacol. Sci., 13: 134-136, 1992.
67. Rowinsky, E. K., Cazenave, L. A., and Donehower, R. C. Taxol: a novel investigational antimicrotubule agent. J. Natl. Cancer Inst., 82: 1247-1259, 1990.
68. Donaldson, K. L., Goolsby, G. L., and Wahl, A. F. Cytotoxicity of the anticancer agents cisplatin and taxol during cell proliferation and the cell cycle. Int. J. Cancer, 57: 847-855, 1994.
69. Wahl, A. F., Donaldson, K. L., Fairchild, C., Lee, F. Y., Foster, S. A., Demers, G. W., and Galloway, D. A. Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nat. Med., 2: 72-79, 1996.
70. Bhalla, K., Ibrado, A. M., Tourkina, E., Tang, C., Grant, S., Bullock, G., Huang, Y., Ponnathpur, V., and Mahoney, M. E. High-dose mitoxantrone induces programmed cell death or apoptosis in human myeloid leukemia cells. Blood, 82: 3133-3140, 1993.
71. Liu, Y., Bhalla, K., Hill, C., and Priest, D. G. Evidence for involvement of tyrosine phosphorylation in taxol-induced apoptosis in a human ovarian tumor cell line. Biochem. Pharmacol., 48: 1265-1272, 1994.
72. Huang, S. M., Bock, J. M., and Harari, P. M. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res., 59: 1935-1940, 1999.
73. Gerber, H. P., Dixit, V., and Ferrara, N. Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J. Biol. Chem., 273: 13313-13316, 1998.
74. Nor, J. E., Christensen, J., Mooney, D. J., and Polverini, P. J. Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial survival and induction of Bcl-2 expression. Am. J. Pathol., 154: 375-384, 1998.
75. Katoh, O., Takahashi, T., Oguri, T., Kuramoto, K., Mihara, K., Kobayashi, M., Hirata, S., and Watanabe, H. Vascular endothelial growth factor inhibits apoptotic death in hematopoietic cells after exposure to chemotherapeutic drugs by inducing MCL1 acting as an antiapoptotic factor. Cancer Res., 58: 5565-5569, 1998.
76. Mazure, N. M., Chen, E. Y., Laderoute, K. R., and Giaccia, A. J. Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-ras-transformed cells though hypoxia inducible factor-1 transcriptional element. Blood, 90: 3322-3331, 1997.
77. Gerber, H. P., McMurtrey, A., Kowalski, J., Yan, M., Keyt, B. A., Dixit, V., and Ferrara, N. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J. Biol. Chem., 273: 30336-30343, 1998.
78. Thakker, G. D., Hajjar, D. P., Muller, W. A., and Rosengart, T. K. The role of phosphatidylinositol 3-kinase in vascular endothelial growth factor signaling. J. Biol. Chem., 274: 10002-10007, 1999.
79. Redlitz, A., Daum, G., and Sage, E. H. Angiostatin diminishes activation of the mitogen-activated protein kinases ERK-1 and ERK-2 in human dermal microvascular endothelial cells. J. Vasc. Res., 36: 28-34, 1999.
80. Mukhopadhyay, D., Nagy, J. A., Manseau, E. J., and Dvorak, H. F. Vascular permeability factor/vascular endothelial growth factor-mediated signaling in mouse mesentery vascular endothelium. Cancer Res., 58: 1278-1284, 1998.
81. Meeson, A. P., Argilla, M., Ko, K., Witte, L., and Lang, R. A., VEGF-deprivation-induced apoptosis is a component of programmed capillary regression. Development (Camb.), 126: 1407-1415, 1999.
82. Gupta, K., Kshirsagar, S., Li, W., Gui, L., Ramakrishnan, S., Gupta, P., Law, P. Y., and Hebbel, R. P. VEGF prevents apoptosis of human microvascular endothelial cells via opposing effects on MAPK/ERK and SAPK/JNK signaling. Exp. Cell Res., 247: 495-504, 1999.
83. Benjamin, L. E., Golijanin, D., Itin, A., Pode, D., and Keshet, E. Selective ablation of immature blood vessels in established human tumors follows vascular growth factor withdrawal. J. Clin. Investig., 103: 159-165, 1999.
84. Carmeliet, P., Dor, Y., Herbert, J. M., Fukumura, D., Brusselmans, K., Dewerchin, M., Neeman, M., Bono, F., Abramovitch, R., Maxwell, P., Koch, C. J., Ratcliffe, P., Moons, L., Jain, R. K., Collen, D., and Keshet, E. Role of HIF-α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature (Lond.), 394: 485-490, 1998.